VERNON HILLS, Ill.--(BUSINESS WIRE)--Winston Laboratories, Inc., a wholly-owned subsidiary of Winston Pharmaceuticals, Inc. (“Winston”) (OTC PINK: WPHM), a pharmaceutical company focused on developing and commercializing novel pain management therapies, announced that it has submitted a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for approval to market its civamide (zucapsaicin) 0.075% cream, CIVANEX®, for the treatment of signs and symptoms of osteoarthritis of the knee. Winston anticipates that the application will be subject to a standard review with a Prescription Drug User Fee Act (PDUFA) date in the second half of 2011.
